Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation

N W J Bulkmans1, S Bulk, M S Ottevanger

  • 1Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.

Journal of Clinical Pathology
|September 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of colorectal cancer and participation in fecal immunochemical test-based screening.

Public health·2025
Same author

[Is it a sexually transmitted disease?]

Nederlands tijdschrift voor geneeskunde·2024
Same author

Perspective of obstetric care-providers on being involved in cervical cancer screening during antenatal care in the Netherlands.

Cancer medicine·2024
Same author

Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor-stroma ratio in colon cancer.

ESMO open·2024
Same author

The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.

International journal of cancer·2024
Same author

Resilience of the Dutch HPV-based cervical screening programme during the COVID-19 pandemic.

Public health·2023

Adding high-risk human papillomavirus (hrHPV) testing to cervical screening programs enhances efficacy without reducing participation rates. This approach integrates hrHPV testing into existing cytology screening, addressing concerns about perceived links to sexually transmitted infections.

Area of Science:

  • Gynecologic Oncology
  • Public Health
  • Molecular Diagnostics

Background:

  • Cervical screening programs aim to reduce cancer incidence and mortality.
  • High-risk human papillomavirus (hrHPV) testing improves screening efficacy but raises concerns about participation.
  • The POpulation-BAsed SCreening study AMsterdam (POBASCAM) trial investigated hrHPV integration.

Purpose of the Study:

  • To evaluate the impact of adding hrHPV testing to cervical screening on participation rates.
  • To assess the feasibility of integrating hrHPV testing into established screening programs.
  • To address potential barriers to participation associated with hrHPV testing.

Main Methods:

  • The study analyzed participation rates before and after the implementation of hrHPV testing in a defined region.

Related Experiment Videos

  • The POpulation-BAsed SCreening study AMsterdam (POBASCAM) trial provided the framework for this evaluation.
  • Data on screening participation were collected and compared across different time periods.

    • Main Results:

    • The participation rate increased from 58.7% before hrHPV implementation to 61.4% after its addition.
    • This increase in participation was statistically significant (p<0.001).
    • The study found no decrease in participation rates following the introduction of hrHPV testing.

    Conclusions:

    • Integrating high-risk human papillomavirus (hrHPV) testing into cervical screening programs is feasible.
    • The addition of hrHPV testing can be achieved without a negative impact on screening participation.
    • This strategy enhances cervical cancer screening efficacy while maintaining or improving population engagement.